What does CUSIP 008064206 represent in this 13F holders report?

CUSIP 008064206 is the security identifier for JBIO - Jade Biosciences, Inc. - Common Stock used to aggregate holder disclosures.

How many institutions held JBIO - Jade Biosciences, Inc. - Common Stock in Q1 2026?

39 institutional investors reported JBIO - Jade Biosciences, Inc. - Common Stock for Q1 2026. Use the holders table for investor-level position and value details.

Jade Biosciences, Inc. - Common Stock (JBIO)

CUSIP: 008064206

Q1 2026 13F Holders as of 31 Mar 2026

Type / Class: Equity / Common Stock
Shares outstanding: 48,847,340
Total 13F shares: 5,365,696
Share change: -153,077
Total reported value: $75,388,433
Price per share: $14.05
Number of holders: 39
Value change: -$2,096,192
Number of buys: 18
Number of sells: 17

Quarterly Holders Quick Answers

What is CUSIP 008064206?
CUSIP 008064206 identifies JBIO - Jade Biosciences, Inc. - Common Stock in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Previous quarter: Q4 2025

Recent filing periods for CUSIP 008064206:

Q1 2026 Q4 2025 Q3 2025 Q2 2025

Top shareholders of JBIO - Jade Biosciences, Inc. - Common Stock (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
FMR LLC	13F 13D/G	Company	15% from 13D/G	6,894,488	$106,381,950	—	31 Dec 2025	13F 13D/G
Fairmount Funds Management LLC	13D/G 3/4/5 13F	Director, 10%+ Owner · Company	20%	10,353,875	$89,373,614	+$26,797,898	06 Oct 2025	13D/G 3/4/5 13F
Sofinnova Venture Partners X, L.P.	3/4/5 13D/G	10%+ Owner · Sofinnova Venture Partners X, L.P. ("SVP X")	0.3% from 13D/G	3,758,686	$73,294,377	—	02 Jul 2021	3/4/5 13D/G
Venrock Healthcare Capital Partners III, L.P.	13D/G	—	9.9%	5,115,862	$70,905,847	+$26,271,533	31 Dec 2025	13D/G
RA CAPITAL MANAGEMENT, L.P.	13F 13D/G 3/4/5	Company · 10%+ Owner	7% from 13D/G	3,671,083	$56,644,811	—	31 Dec 2025	13F 13D/G 3/4/5
Bellevue Group AG	13F 13D/G	Company	6.8% from 13D/G	3,341,103	$51,553,219	—	31 Dec 2025	13F 13D/G
David S. Grayzel	3/4/5	Director	— mixed-class rows	1,811,732 mixed-class rows	$50,853,006	—	05 Jun 2024	3/4/5
VR Adviser, LLC	13F	Company	6.6%	3,220,364	$49,690,217	—	31 Dec 2025	13F
Atlas Venture Fund XII, L.P.	3/4/5 13D/G	10%+ Owner · Atlas Venture Associates XII, L.P.	0.2% from 13D/G	2,327,909	$45,394,226	—	15 Jul 2022	3/4/5 13D/G
BlackRock, Inc.	13F 13D/G	Company	4.7% from 13D/G	2,870,313	$44,288,930	—	31 Dec 2025	13F 13D/G
JANUS HENDERSON GROUP PLC	13D/G	—	6.2%	3,063,457	$42,459,514	$0	31 Dec 2025	13D/G
Cormorant Asset Management, LP	3/4/5	Former 10% Owner	— class O/S missing	2,030,691	$39,598,475	—	02 Jul 2021	3/4/5
VANGUARD GROUP INC	13F 13D/G	Company · The Vanguard Group	4.2% from 13D/G	2,095,767	$32,337,685	—	31 Dec 2025	13F 13D/G
BAKER BROS. ADVISORS LP	13F	Company	3.4%	1,641,137	$25,322,744	—	31 Dec 2025	13F
Remedium Capital Partners, LLC	13F	Company	3.2%	1,577,750	$24,345,000	—	31 Dec 2025	13F
Versant Venture Management, LLC	13F	Company	3.1%	1,525,820	$23,543,403	—	31 Dec 2025	13F
RTW INVESTMENTS, LP	13F	Company	3%	1,449,273	$22,362,282	—	31 Dec 2025	13F
Avidity Partners Management LP	13F	Company	2.9%	1,400,708	$21,612,924	—	31 Dec 2025	13F
Samsara BioCapital, LLC	13F	Company	2%	968,798	$14,948,553	—	31 Dec 2025	13F
DRIEHAUS CAPITAL MANAGEMENT LLC	13F	Company	1.8%	887,179	$13,689,172	—	31 Dec 2025	13F
MARSHALL WACE, LLP	13F	Company	1.8%	875,273	$13,505,462	—	31 Dec 2025	13F
Aberdeen Group plc	13F	Company	1.8%	867,284	$13,382,192	—	31 Dec 2025	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	1.7%	841,808	$12,991,338	—	31 Dec 2025	13F
GREAT POINT PARTNERS LLC	13F	Company	1.7%	806,273	$12,440,792	—	31 Dec 2025	13F
Soleus Capital Management, L.P.	13F	Company	1.6%	796,744	$12,293,760	—	31 Dec 2025	13F
Frazier Life Sciences Public Fund, L.P.	13D/G	—	4.2%	1,384,646	$11,949,495	+$379,228	30 Sep 2025	13D/G
Affinity Asset Advisors, LLC	13F	Company	1.5%	714,956	$11,031,771	—	31 Dec 2025	13F
STATE STREET CORP	13F	Company	1.3%	642,921	$9,920,271	—	31 Dec 2025	13F
Point72 Asset Management, L.P.	13F	Company	1.1%	558,474	$8,617,254	—	31 Dec 2025	13F
ORBIMED ADVISORS LLC	13F	Company	1.1%	531,163	$8,195,845	—	31 Dec 2025	13F
Opaleye Management Inc.	13F	Company	0.88%	427,608	$6,597,991	—	31 Dec 2025	13F
Logos Global Management LP	13F	Company	0.81%	395,000	$6,094,850	—	31 Dec 2025	13F
Timothy P. Noyes	3/4/5	CHIEF EXECUTIVE OFFICER, Director	— class O/S missing	343,381	$5,621,147	—	16 May 2024	3/4/5
Andrew James King	3/4/5	Chief Scientific Officer & Head of Research and Development	— mixed-class rows	633,613 mixed-class rows	$5,351,526	—	12 Feb 2026	3/4/5
Ikarian Capital, LLC	13F	Company	0.61%	300,000	$4,629,001	—	31 Dec 2025	13F
Caption Management, LLC	13F	Company	0.61%	297,095	$4,584,176	—	31 Dec 2025	13F
ExodusPoint Capital Management, LP	13F	Company	0.59%	287,587	$4,437,467	—	31 Dec 2025	13F
NORTHERN TRUST CORP	13F	Company	0.56%	274,101	$4,229,379	—	31 Dec 2025	13F
Invesco Ltd.	13F	Company	0.41%	199,727	$3,081,788	—	31 Dec 2025	13F
AMERIPRISE FINANCIAL INC	13F	Company	0.38%	187,254	$2,889,330	—	31 Dec 2025	13F
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	13F	Company	0.26%	125,772	$1,940,662	—	31 Dec 2025	13F
Nuveen, LLC	13F	Company	0.25%	124,545	$1,921,729	—	31 Dec 2025	13F
Bank of New York Mellon Corp	13F	Company	0.24%	114,906	$1,772,999	—	31 Dec 2025	13F
Sofinnova Investments, Inc.	13F	Company	0.22%	107,391	$1,657,043	—	31 Dec 2025	13F
WELLINGTON MANAGEMENT GROUP LLP	13F	Company	0.21%	102,620	$1,583,426	—	31 Dec 2025	13F
Hunter Gillies	3/4/5	CHIEF MEDICAL OFFICER	— mixed-class rows	89,112 mixed-class rows	$1,504,308	—	13 Jun 2024	3/4/5
UBS Group AG	13F	Company	0.2%	96,786	$1,493,408	—	31 Dec 2025	13F
Woodline Partners LP	13F	Company	0.17%	82,056	$1,266,124	—	31 Dec 2025	13F
BOOTHBAY FUND MANAGEMENT, LLC	13F	Company	0.17%	81,148	$1,252,114	—	31 Dec 2025	13F
MORGAN STANLEY	13F	Company	0.16%	79,767	$1,230,805	—	31 Dec 2025	13F

Institutional Holders of Jade Biosciences, Inc. - Common Stock (JBIO) as of Q1 2026

As of 31 Mar 2026, Jade Biosciences, Inc. - Common Stock (JBIO) was held by 39 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 5,365,696 shares. The largest 10 holders included VANGUARD CAPITAL MANAGEMENT LLC, Versant Venture Management, LLC, Aberdeen Group plc, VANGUARD FIDUCIARY TRUST CO, VANGUARD PORTFOLIO MANAGEMENT LLC, Connor, Clark & Lunn Investment Management Ltd., Russell Investments Group, Ltd., Bank of New York Mellon Corp, UBS Group AG, and Nuveen, LLC. This page lists 39 institutional shareholders reporting positions in this security for the Q1 2026 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q1 2026 vs Q4 2025 Across Filers

Q4 2025 holders

102

Q1 2026 holders

Holder diff

-63

Investor	Q4 2025 Shares	Q1 2026 Shares	Share Diff	Share Chg %	Q4 2025 Value $	Q1 2026 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.